Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Peter Kabos to Treatment Outcome

This is a "connection" page, showing publications Peter Kabos has written about Treatment Outcome.

 
Connection Strength
 
 
 
0.143
 
  1. Schade H, Davis L, Kabos P. Middle-Aged Man With Acute Thrombocytopenia Subsequent to Fluorouracil and Oxaliplatin Chemotherapy for Colorectal Cancer. Oncology (Williston Park). 2016 Nov 15; 30(11):992-4, 1000-1.
    View in: PubMed
    Score: 0.043
  2. Jasem J, Altoos B, Fisher CM, Elias AD, Kounalakis N, Borges VF, Kabos P. Multiple Hepatic Lesions in a Patient With a History of DCIS. Oncology (Williston Park). 2015 Sep; 29(9):669-70, 678-9.
    View in: PubMed
    Score: 0.040
  3. Shagisultanova E, Parris H, Liu L, Giangiuli S, Gao D, Diamond JR, Acharya-Leon R, Kabos P, Borges VF. Sequential Therapy With HER2 Tyrosine Kinase Inhibitors in Patients With HER2-Positive Metastatic Breast Cancer. Clin Breast Cancer. 2025 Oct; 25(7):643-649.e1.
    View in: PubMed
    Score: 0.019
  4. Travers SS, Fisher CM, Kabos P, Cittelly DM, Ormond DR. Breast cancer brain metastases localization and risk of hydrocephalus: a single institution experience. J Neurooncol. 2023 May; 163(1):115-121.
    View in: PubMed
    Score: 0.017
  5. Stumpf PK, Cittelly DM, Robin TP, Carlson JA, Stuhr KA, Contreras-Zarate MJ, Lai S, Ormond DR, Rusthoven CG, Gaspar LE, Rabinovitch R, Kavanagh BD, Liu A, Diamond JR, Kabos P, Fisher CM. Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4. Clin Cancer Res. 2019 07 01; 25(13):3946-3953.
    View in: PubMed
    Score: 0.013
  6. Banerji U, Dean EJ, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHM. A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers. Clin Cancer Res. 2018 05 01; 24(9):2050-2059.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)